March 15, 2026
High hopes, low patience
Cannabinoids remove plaque-forming Alzheimer's proteins from brain cells
Weed zaps brain gunk in a dish — commenters: “old news,” “nothingburger”
TLDR: A 2016 Salk lab study says THC helped clear Alzheimer’s‑linked gunk and calm inflammation in brain cells, but it’s not human evidence. Commenters roast the rerun as in‑vitro hype—mixing Doritos jokes with cautious hope and demands for real trials—because Alzheimer’s is terrifying and only clinical results will count.
It’s back in the feed: a 2016 Salk Institute lab study claims THC—the psychoactive ingredient in marijuana—helped lab‑grown human neurons clear amyloid beta (the sticky protein tied to Alzheimer’s) and cooled inflammation. Sounds huge, right? Except it’s cell‑dish science, not people, and the comments instantly split between high hopes and hard eye‑rolls.
One user boils the mood down to a bumper sticker: Pro: Salk. Con: preliminary, in vitro. Another asks the uncomfortable question—did anything ever come of it? Then the skeptics drop the hammer: there are hundreds of compounds that clean up amyloid in a petri dish; until humans show benefit, it’s a “decade‑old nothingburger.” In the middle, a vulnerable voice admits weed triggers panic attacks but fears Alzheimer’s enough to try if it ever becomes a legit preventative—yet doubts it’ll pan out. Comic relief arrives with a classic stoner jab: “Remove them and replace them with… Doritos?” Meanwhile, reminders that exercise makes your body’s own THC‑like molecules (endocannabinoids) spark “go for a jog, not a joint” quips.
Verdict from the crowd: big curiosity, bigger caution. Everyone wants a breakthrough, but nobody’s crowning cannabis a cure until real clinical trials show results.
Key Points
- •Preliminary in vitro studies at the Salk Institute show THC and other cannabinoids promote removal of amyloid beta from human neurons.
- •THC exposure reduced amyloid beta levels and suppressed associated inflammatory responses in nerve cells, improving cell survival.
- •Findings suggest cannabinoids affect both inflammation and amyloid beta accumulation in neurons, offering mechanistic insight.
- •Researchers emphasize the work is exploratory and conducted in lab models; clinical trials are needed to assess therapeutic use.
- •Related research identified J147 as reducing amyloid beta and inflammation, helping reveal endocannabinoids’ role in these processes.